

# CITATION REPORT

List of articles citing

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

DOI: 10.1016/0021-9150(96)05852-2  
Atherosclerosis, 1996, 124 Suppl, S11-20.

**Source:** <https://exaly.com/paper-pdf/26843002/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
595	Is cholesterol the major lipoprotein risk factor in coronary heart disease?--a Franco-Scottish overview. <b>1997</b> , 13, 603-16		8
594	Major locus influencing plasma APO-A1 levels also controls plasma HDL3-C concentrations. <b>1998</b> , 15, 237-49		2
593	VLDL compositional changes and plasma levels of triglycerides and high density lipoprotein. <b>1998</b> , 269, 107-24		20
592	Genetics of lipoprotein disorders. <b>1998</b> , 27, 521-50		25
591	High Density Lipoproteine, koronare Herzkrankheit und reverser Cholesterin-Transport. <b>1999</b> , 23, 104-107		
590	Elevation of high-density lipoprotein cholesterol in humans during long-term therapy with amiodarone. <b>1999</b> , 83, 296-300, A7		3
589	Lipoprotein atherogenicity: an overview of current mechanisms. <i>Proceedings of the Nutrition Society</i> , <b>1999</b> , 58, 163-9	2.9	126
588	Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. <b>2000</b> , 160, 1177-84		131
587	How high-density lipoprotein protects against the effects of lipid peroxidation. <b>2000</b> , 11, 383-8		136
586	Familial associations of lipid profiles: a generalized estimating equations approach. <b>2000</b> , 19, 3345-57		14
585	The epidemiology of low levels of high-density lipoprotein cholesterol in patients with and without coronary artery disease. <b>2000</b> , 86, 11L-14L		79
584	Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , <b>2000</b> , 2, 58-63	6	6
583	Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. <i>Circulation</i> , <b>2000</b> , 101, E3-E11	16.7	72
582	Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. <b>2000</b> , 20, 2670-6		173
581	Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations. <i>Atherosclerosis</i> , <b>2000</b> , 152, 457-68	3.1	75
580	Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. <b>2000</b> , 35, 640-6		19
579	Results of Expert Meetings: Obesity and Cardiovascular Disease. Obesity, the metabolic syndrome, and cardiovascular disease. <b>2001</b> , 142, 1108-16		94

578	Dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans: a meta-analysis. <b>2001</b> , 73, 885-91		222
577	Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. <b>2001</b> , 87, 476-9, A7		81
576	Increasing high-density lipoprotein cholesterol: an update on fenofibrate. <b>2001</b> , 88, 30N-36N		72
575	Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. <b>2001</b> , 2, S1-73		267
574	[HDL metabolism]. <b>2001</b> , 39, 321-7		0
573	Vascular reactivity in hypogonadal men is reduced by androgen substitution. <b>2002</b> , 87, 5030-7		69
572	HDL and triglyceride as therapeutic targets. <b>2002</b> , 13, 605-16		41
571	Genetics and prevention: a new look at high-density lipoprotein cholesterol. <b>2002</b> , 10, 61-71		13
570	The paraoxonase gene family and coronary heart disease. <b>2002</b> , 13, 357-62		77
569	HDL and arteriosclerosis: beyond reverse cholesterol transport. <i>Atherosclerosis</i> , <b>2002</b> , 161, 1-16	3.1	449
568	Dynamics of reverse cholesterol transport: protection against atherosclerosis. <i>Atherosclerosis</i> , <b>2002</b> , 161, 245-54	3.1	116
567	Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. <i>Atherosclerosis</i> , <b>2002</b> , 164, 361-9	3.1	105
566	Fisiopatología de la enfermedad aterotrombótica coronaria. <b>2002</b> , 14, 258-271		1
565	Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels. <i>American Journal of Cardiovascular Drugs</i> , <b>2002</b> , 2, 125-32; discussion 133-4	4	8
564	HDL in risk prediction and its direct and indirect involvement in atherogenesis. <b>2002</b> , 3, 3-12		13
563	Paraoxonase and coronary heart disease. <b>2002</b> , 3, 49-55		116
562	Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL. <b>2002</b> , 3, 23-30		31
561	Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. <b>2002</b> , 24, 1426-38		9

560	The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. <b>2002</b> , 90, 139-43	167
559	Lipoprotein disorders and cardiovascular risk. <b>2003</b> , 26, 267-87	50
558	Longevity-associated mitochondrial DNA 5178 A/C polymorphism modulates effects of daily drinking and cigarette consumption on serum triglyceride levels in middle-aged Japanese men. <b>2003</b> , 38, 1071-6	21
557	Introduction. <b>2003</b> , 91, 1-2	1
556	Therapeutic targets in cardiovascular disease: a case for high-density lipoprotein cholesterol. <b>2003</b> , 91, 40E-43E	10
555	Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. <b>2003</b> , 33, 1051-69	193
554	Effects of androgen replacement on metabolism and physical performances in male hypogonadism. <b>2003</b> , 26, 886-92	18
553	A retrospective meta-analysis of the efficacy and tolerability of fenofibrate 300 mg/d on high-density lipoprotein cholesterol levels in randomized, double-blind, comparative studies conducted in Japan. <b>2003</b> , 64, 634-44	1
552	Old and new cardiovascular risk factors: from unresolved issues to new opportunities. <b>2003</b> , 4, 5-17	27
551	Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. <b>2003</b> , 25, 1670-86	40
550	Cellular phospholipid and cholesterol efflux in high-density lipoprotein deficiency. <i>Circulation</i> , <b>2003</b> , 107, 1366-71	16.7 30
549	Ezetimibe. <i>American Journal of Cardiovascular Drugs</i> , <b>2003</b> , 3, 67-76; discussion 77-8	4 29
548	A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naïve human immunodeficiency virus-infected patients: a randomized controlled study. <b>2003</b> , 88, 5186-92	43
547	Optimal therapy of low levels of high density lipoprotein-cholesterol. <i>American Journal of Cardiovascular Drugs</i> , <b>2003</b> , 3, 53-65	4 13
546	Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. <b>2003</b> , 77, 1146-55	1942
545	Identification and Management of Vascular Risk: Beyond Low Density Lipoprotein Cholesterol. <b>2003</b> , 51, 521-531	3
544	Is the decreased high-density lipoprotein cholesterol in the metabolic syndrome due to cellular lipid efflux defect?. <b>2004</b> , 89, 761-4	19
543	Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <b>2004</b> , 20, 627-37	62

542	Contribution of cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase to HDL size distribution. <b>2004</b> , 30, 403-15		23
541	Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. <b>2004</b> , 279, 45085-92		110
540	A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. <i>Journal of Lipid Research</i> , <b>2004</b> , 45, 948-53	6.3	175
539	A review of the treatment guidelines on the management of low levels of high-density lipoprotein cholesterol. <b>2004</b> , 102, 61-6		10
538	Taq1B polymorphism of CETP gene on lipid abnormalities in patients with type II diabetes mellitus. <b>2004</b> , 13, 889		1
537	HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. <b>2004</b> , 24, 871-7		85
536	Dyslipidemia in patients with angiographically confirmed coronary artery disease--an opportunity for improvement. <b>2004</b> , 27, 577-80		
535	The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. <i>American Journal of Cardiovascular Drugs</i> , <b>2004</b> , 4, 211-7	4	100
534	Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. <i>American Journal of Cardiovascular Drugs</i> , <b>2004</b> , 4, 227-46	4	77
533	Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. <i>American Journal of Cardiovascular Drugs</i> , <b>2004</b> , 4, 299-314	4	22
532	HDL: the metabolism, function, and therapeutic importance. <b>2004</b> , 104, 119-37		107
531	Prevention and treatment of the metabolic syndrome. <b>2004</b> , 55, 589-612		109
530	Importancia del colesterol ligado a lipoproteínas de alta densidad (cHDL) en la prevención del riesgo cardiovascular. Recomendaciones del Foro HDL. <b>2004</b> , 16, 262-280		
529	Alteraciones metabólicas y enfermedad cardiovascular. <b>2004</b> , 21, 331-333		
528	A comparison of HDL and LDL cholesterol for prevalent coronary calcification. <b>2004</b> , 95, 55-60		31
527	Design, synthesis, and biological evaluation of thio-containing compounds with serum HDL-cholesterol-elevating properties. <b>2004</b> , 47, 681-95		43
526	High-density lipoproteins: multifunctional vanguards of the cardiovascular system. <b>2004</b> , 2, 417-30		13
525	HDL: a recipe for longevity. <b>2004</b> , 5, 25-31		31

524	Dyslipidemia in the metabolic syndrome. <b>2004</b> , 2, 3-34		1
523	Defining the prevalence of low HDL-C in a European cohort of dyslipidaemic patients. <b>2005</b> , 7, F23-F26		5
522	Calculating global risk: the key to intervention. <b>2005</b> , 7, F9-F14		5
521	Raising HDL-cholesterol and lowering CHD risk: does intervention work?. <b>2005</b> , 7, F15-F22		4
520	HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. <b>2005</b> , 16, 652-7		5
519	Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. <b>2005</b> , 258, 94-114		467
518	High-density lipoprotein apolipoprotein A-I kinetics in obesity. <b>2005</b> , 13, 1008-16		36
517	Nutrition is a powerful independent risk factor for coronary heart disease in women--The CORA study: a population-based case-control study. <b>2005</b> , 59, 1201-7		44
516	Effects of cholesterol ester transfer protein Taq1B gene polymorphism on serum lipoprotein levels in Turkish coronary artery disease patients. <b>2005</b> , 23, 23-8		25
515	Dibenzodioxocinones--a new class of CETP inhibitors. <b>2005</b> , 15, 3611-4		29
514	Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. <b>2005</b> , 19, 135-9		26
513	Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid. <b>2005</b> , 19, 415-22		18
512	Modern fat technology: what is the potential for heart health?. <i>Proceedings of the Nutrition Society</i> , <b>2005</b> , 64, 379-86	2.9	36
511	Perceptual quality of H.264/AVC deblocking filter. <b>2005</b> ,		5
510	Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. <b>2005</b> , 5, S1-S15		
509	The realities of dyslipidaemia in metabolic syndrome and diabetes. <b>2005</b> , 5, S7-S11		
508	A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. <b>2005</b> , 142, 95-104		178
507	Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. <b>2005</b> , 25, 2185-91		233

506 Konzepte der differenzierten Lipidtherapie. **2005**, 1, 395-412

505 The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor. *Diabetes and Vascular Disease Research*, **2005**, 2 Suppl 1, S1-8 3.3 4

504 The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. **2005**, 90, 4198-204 54

503 Managing abnormal blood lipids: a collaborative approach. *Circulation*, **2005**, 112, 3184-209 16.7 164

502 ARBITER 2: targeting HDL to retard atherosclerosis progression: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. **2005**, 5, 78-80 1

501 Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. **2005**, 7, F34-F40 15

500 Lipids for psychiatrists - an overview. **2005**, 19, 66-75 14

499 Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit. *Atherosclerosis*, **2005**, 181, 233-40 3.1 22

498 The potential for CETP inhibition to reduce cardiovascular disease risk. **2006**, 22, 2467-78 8

497 Síndrome metabólico: ¿cómo diagnosticarlo y cómo tratarlo?. **2006**, 18, 49-55

496 A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. **2006**, 7, 21-9 4

495 Prevalencia de factores de riesgo vascular en la población laboral española. **2006**, 59, 421-430 51

494 Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. **2006**, 47, 492-9 139

493 Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene. **2006**, 368, 149-54 10

492 Modified HDL: biological and physiopathological consequences. **2006**, 16, 371-86 63

491 Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. **2006**, 12, 745-51 27

490 1.3 Klassische Risikofaktoren. **2006**,

489 Risk factors for severe coronary artery disease - a case-control study of patients who have undergone coronary artery bypass grafting. *Journal of Atherosclerosis and Thrombosis*, **2006**, 13, 62-7 4 3

488	Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux. <b>2006</b> , 136, 877-81	26
487	Dyslipidaemia and global cardiovascular risk: clinical issues. <b>2006</b> , 8, F40-F46	19
486	Diabetic dyslipidaemia: the triad. <b>2006</b> , 8, F30-F33	1
485	The gap between theory and practice: what do the trials tell us?. <b>2006</b> , 8, F10-F16	
484	Genetics of high-density lipoproteins. <b>2006</b> , 21, 329-35	18
483	HDL and endothelial function: from molecular mechanisms to clinical observations. <b>2006</b> , 1, 343-355	2
482	Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. <b>2006</b> , 1, 129-47	42
481	Progression of severe atherosclerosis and increased arterial pulse pressure in the newly developed heritable mixed hyperlipidaemic rabbits. <b>2006</b> , 33, 221-6	4
480	Levels of matrix metalloproteinases-8 and -9 with simultaneous presence of periodontal pathogens in gingival crevicular fluid as well as matrix metalloproteinase-9 and cholesterol in blood. <b>2006</b> , 41, 411-7	58
479	High-density lipoprotein apolipoprotein A-I kinetics: comparison of radioactive and stable isotope studies. <b>2006</b> , 36, 626-32	4
478	High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. <b>2006</b> , 16, 799-808	16
477	Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. <b>2006</b> , 11, 379-401	79
476	[Long-standing therapy of the metabolic syndrome in diabetics after coronary artery bypass surgery]. <b>2006</b> , 95 Suppl 1, i110-6	1
475	Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. <b>2006</b> , 551, 80-6	22
474	Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. <b>2006</b> , 98, 711-7	63
473	Emerging strategies for increasing high-density lipoprotein. <b>2006</b> , 98, 1542-9	34
472	Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. <b>2006</b> , 15, 301-12	44
471	Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. <b>2006</b> , 111, 893-908	104



470	Epidemiology of low HDL-cholesterol: results of studies and surveys. <b>2006</b> , 8, F17-F22		23
469	One third of the variability in HDL-cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia: The Paris La Pitié Study. <b>2006</b> , 22, 1149-60		9
468	Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins. <i>Circulation</i> , <b>2006</b> , 114, 1315-20; discussion 1320	16.7	7
467	Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. <b>2006</b> , 101, 1727-32		124
466	Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. <b>2006</b> , 40, 1274-9		21
465	NAUTILUS (Safety and tolerability of Niaspan <sup>®</sup> ): a subgroup analysis in patients with diabetes. <b>2006</b> , 6, 127-133		2
464	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <b>2007</b> , 8, 2267-77		9
463	High-density lipoprotein cholesterol: an emerging target for stroke treatment. <b>2007</b> , 38, 1104-9		43
462	Present-day uses of niacin: effects on lipid and non-lipid parameters. <b>2007</b> , 8, 1711-7		14
461	Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study. <b>2007</b> , 10, 225-37		12
460	Sources of variability of plasma HDL-cholesterol levels. <b>2007</b> , 2, 557-569		2
459	Increasing apoA-I production as a target for CHD risk reduction. <b>2007</b> , 17, 616-28		27
458	A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia. <b>2007</b> , 88, 751-7		68
457	Palmitic acid in HDL is associated to low apo A-I fractional catabolic rates in vivo. <b>2007</b> , 378, 53-8		10
456	Relationship between apolipoproteins and the alteration of HDL subclasses in hyperlipidemic subjects. <b>2007</b> , 383, 65-72		7
455	HDL-knowledge in the lay public: results of a representative population survey. <i>Atherosclerosis</i> , <b>2007</b> , 195, 195-8	3.1	25
454	Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. <b>2007</b> , 80, 673-82		71
453	Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. <i>Current Atherosclerosis Reports</i> , <b>2007</b> , 9, 81-8	6	9

452	Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. <i>Atherosclerosis</i> , <b>2007</b> , 190, 397-407	3.1	27
451	HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. <b>2007</b> , 357, 1301-10		1190
450	Molecular Mechanisms Responsible for the Anti-Inflammatory and Protective Effect of High-Density Lipoprotein on the Endothelium. <b>2007</b> , 14, 21-31		1
449	Risk of cardiovascular events in patients at optimal values for combined lipid parameters. <b>2007</b> , 23, 553-63		41
448	Fatty acid profile of coconut oil in relation to nut maturity and season in selected cultivars/hybrids. <b>2007</b> , 109, 272-279		9
447	Cholesterol ester transfer protein (CETP) and atherosclerosis. <b>2007</b> , 4, 137-145		4
446	The anti-atherogenic properties of HDL particles. <b>2007</b> , 1303, 103-110		5
445	Effect of drugs on high-density lipoprotein. <i>Journal of Clinical Lipidology</i> , <b>2007</b> , 1, 74-87	4.9	3
444	Lipoprotein Subfraction Analysis Using Nuclear Magnetic Resonance Spectroscopy. 217-250		1
443	Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 467-79	4.4	14
442	Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2007</b> , 14, 155-8	4	169
441	. <b>2007</b> ,		
440	. <b>2007</b> ,		6
439	Genetics of High-Density Lipoproteins. <b>2007</b> , 465-490		
438	Low HDL-C predicts the onset of transplant vasculopathy in pediatric cardiac recipients on pravastatin therapy. <b>2007</b> , 11, 481-90		4
437	A protective role of a cholesteryl ester transfer protein gene variant towards ischaemic stroke in Sardinians. <b>2007</b> , 262, 555-61		10
436	HDL-c is a powerful lipid predictor of cardiovascular diseases. <b>2007</b> , 61, 1905-13		37
435	Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan). <b>2007</b> , 61, 1914-21		7

434	High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. <b>2007</b> , 8 Suppl 6, S14-23	17
433	Rosuvastatin: The Most Efficient Treatment Option For Patients With Dyslipidemia. <b>2007</b> , 2, 127-141	
432	Unterschiedliche Effekte der Ernährung auf die koronare Herzkrankheit. <b>2007</b> , 48, 1309-1312	
431	Chancen der Ernährung in der Prävention koronarer Herzkrankheit bei Frauen. <b>2007</b> , 1, 114-119	
430	Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. <b>2008</b> , 22, 321-38	103
429	Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). <b>2008</b> , 7, 31	40
428	HDLs activate ADAM17-dependent shedding. <b>2008</b> , 214, 687-93	35
427	Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial. <b>2008</b> , 69, 870-7	16
426	High-density lipoprotein cholesterol, C-reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography. <b>2008</b> , 38, 372-80	22
425	Time to wake up and smell the coffee: antipsychotic medication and schizophrenia. <b>2008</b> , 15, 344-8	10
424	Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g). <b>2008</b> , 102, 1341-7	18
423	Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. <b>2008</b> , 51, 1000-100	79
422	Diabetic dyslipidemia and the metabolic syndrome. <b>2008</b> , 2, 208-222	5
421	HDL-C in post-menopausal women: An important therapeutic target. <b>2008</b> , 124, 275-82	16
420	Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials. <b>2008</b> , 7, 48-58	61
419	Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. <b>2008</b> , 389, 79-86	20
418	HbA1c negatively correlates with LCAT activity in type 2 diabetes. <b>2008</b> , 81, 38-41	19
417	Treatment of low high-density lipoprotein cholesterol. <b>2008</b> , 24, 27C-31C	6

416	Cholesterol ester transfer protein: a therapeutic target in atherosclerosis?. <b>2008</b> , 12, 937-48		5
415	An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages. <i>Journal of Lipid Research</i> , <b>2008</b> , 49, 1322-32	6.3	50
414	Origins of intestinal ABCA1-mediated HDL-cholesterol. <i>Journal of Lipid Research</i> , <b>2008</b> , 49, 2605-19	6.3	32
413	Disorders of high-density lipoprotein biogenesis. <b>2008</b> , 40, 39-47		1
412	Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. <b>2009</b> , 82, 201-11		139
411	Hypolipidaemic effects of fenofibrate and fasting in the herbivorous grass carp ( <i>Ctenopharyngodon idella</i> ) fed a high-fat diet. <b>2008</b> , 100, 1200-12		31
410	Participation of K <sup>+</sup> channels in the endothelium-dependent and endothelium-independent components of the relaxant effect of rosuvastatin in rat aortic rings. <b>2008</b> , 13, 207-13		11
409	HDL-cholesterol modulation and its impact on the management of cardiovascular risk. <b>2008</b> , 45, 122-8		7
408	The 15-lipoxygenase-modified high density lipoproteins 3 fail to inhibit the TNF-alpha-induced inflammatory response in human endothelial cells. <b>2008</b> , 181, 2821-30		21
407	Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population. <i>Journal of Lipid Research</i> , <b>2008</b> , 49, 369-75	6.3	39
406	Prevalence of metabolic syndrome and associated risk factors in Illinois. <b>2008</b> , 23, 130-8		15
405	Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. <b>2008</b> , 15, 142-6		15
404	Acute effects of high-density lipoproteins: biochemical basis and clinical findings. <b>2008</b> , 23, 379-85		19
403	Nicotinic Acid. <b>2009</b> , 298-314		4
402	Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2009</b> , 16, 654-61	4	55
401	Iatrogenic severe depression of high-density lipoprotein cholesterol. <b>2009</b> , 49, 865-71		6
400	Regular exercise and plasma lipid levels associated with the risk of coronary heart disease: a 20-year longitudinal study. <b>2009</b> , 80, 138-45		4
399	How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. <b>2009</b> , 16, 304-14		92

398	Identification of a novel human cellular HDL biosynthesis defect. <b>2009</b> , 30, 2204-12		4
397	Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. <b>2009</b> , 16, 404-23		42
396	Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. <b>2009</b> , 338, b92		331
395	Clinical impact of dyslipidemia for coronary plaque vulnerability in acute coronary syndrome without metabolic syndrome. <b>2009</b> , 54, 394-401		5
394	The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. <b>2009</b> , 4, 113-9		179
393	A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. <b>2009</b> , 31, 586-99		24
392	Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein . <b>2009</b> , 103, 350-4		8
391	Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). <b>2009</b> , 104, 829-34		48
390	Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. <b>2009</b> , 104, 3E-9E		15
389	The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease. <i>Current Atherosclerosis Reports</i> , <b>2009</b> , 11, 329-33	6	10
388	Dyslipidemia therapy update: the importance of full lipid profile assessment. <b>2009</b> , 26, 711-8		10
387	Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. <b>2009</b> , 70, 815-28		57
386	Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c. <b>2009</b> , 39, 680-8		6
385	Prevalence of low HDL cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS study. <b>2009</b> , 63, 71-81		13
384	Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates. <b>2009</b> , 401, 37-41		24
383	Protective roles of HDL, apoA-I and mimetic peptide on endothelial function: through endothelial cells and endothelial progenitor cells. <b>2009</b> , 133, 286-92		17
382	[HDL cholesterol and cardiovascular disease in a population with hypertension and type 2 diabetes mellitus. RICARHD Study]. <b>2009</b> , 209, 227-33		5
381	High-density lipoprotein cholesterol and cardiovascular disease in Spanish hypertensive women. The RIMHA study. <b>2009</b> , 62, 1022-31		1

380	Effects of isoflavone-supplemented soy yogurt on lipid parameters and atherosclerosis development in hypercholesterolemic rabbits: a randomized double-blind study. <b>2009</b> , 8, 40		19
379	Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. <i>Atherosclerosis</i> , <b>2009</b> , 204, 208-15	3.1	69
378	Leukocyte telomere length is associated with HDL cholesterol levels: The Bogalusa heart study. <i>Atherosclerosis</i> , <b>2009</b> , 205, 620-5	3.1	57
377	HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. <i>Atherosclerosis</i> , <b>2009</b> , 206, 611-6	3.1	155
376	Colesterol HDL y enfermedad cardiovascular en mujeres hipertensas de Espa. Estudio RIMHA. <b>2009</b> , 62, 1022-1031		8
375	Altered flow-mediated vasodilatation, low paraoxonase-1 activity, and abnormal high-density lipoprotein subclass distribution in Takayasu's arteritis. <i>Circulation Journal</i> , <b>2009</b> , 73, 760-6	2.9	17
374	Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. <b>2009</b> , 24, 473-82		26
373	Relevance of sphingolipids in the pleiotropic protective effects of high-density lipoproteins. <b>2010</b> , 16, 1468-79		8
372	Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. <b>2010</b> , 153, 800-8		80
371	Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?. <b>2010</b> , 17, 556-61		2
370	Relationship Between Renal Dysfunction and Severity of Coronary Artery Disease in Japanese Patients [Reply] <i>Circulation Journal</i> , <b>2010</b> , 74, 1764-1765	2.9	
369	Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. <b>2010</b> , 99, 723-33		29
368	Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. <b>2010</b> , 105, 821-32		147
367	Auf der Suche nach der richtigen Therapie. <b>2010</b> , 4, 149-151		
366	Fasting cholesteryl ester transfer protein concentration is independently associated with the postprandial decrease in high-density lipoprotein cholesterol concentration after fat-rich meals: the Hoorn prandial study. <b>2010</b> , 59, 854-60		9
365	Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. <b>2010</b> , 126, 314-45		161
364	Cardiometabolic syndrome and its association with education, smoking, diet, physical activity, and social support: findings from the Pennsylvania 2007 BRFSS Survey. <b>2010</b> , 12, 556-64		6
363	An efficient and scalable synthesis of (2R,5)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)phenyl]-4-(trifluoromethyl)-1(2H)-quinolone A potent CETP inhibitor. <b>2010</b> , 47, 1406-1410		

362	Partial filling affinity capillary electrophoresis with cationic poly(vinylpyrrolidone)-based copolymer coatings for studies on human lipoprotein-steroid interactions. <b>2010</b> , 399, 93-101		17
361	Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors. <b>2010</b> , 20, 1432-5		32
360	Novel tetrahydroquinoline derived CETP inhibitors. <b>2010</b> , 20, 1740-3		19
359	KCNQ1 gene polymorphisms are associated with lipid parameters in a Chinese Han population. <b>2010</b> , 9, 35		22
358	Lipid assessment, metabolic syndrome and coronary heart disease risk. <b>2010</b> , 40, 1081-93		24
357	Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects. <b>2010</b> , 18, 342-7		13
356	A guide to lipid modification. <b>2010</b> , 5, 410-416		
355	E-learning Subject of research activities in the Czech Republic. <b>2010</b> ,		
354	[HDL: the yin-yang of cardiovascular disease]. <b>2010</b> , 54, 777-84		9
353	[High frequency of dyslipidemia and impaired fasting glycemia in a high altitude Peruvian population]. <b>2010</b> , 27, 557-61		13
352	A role of the bile salt receptor FXR in atherosclerosis. <b>2010</b> , 30, 1519-28		84
351	Biochemical characterization of cholesteryl ester transfer protein inhibitors. <i>Journal of Lipid Research</i> , <b>2010</b> , 51, 2739-52	6.3	84
350	Peanut consumption and cardiovascular risk. <b>2010</b> , 13, 1581-6		37
349	Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. <b>2010</b> , 31, 149-64		225
348	Enzymatic assessment of cholesterol on electrophoresis gels for estimating HDL size distribution and plasma concentrations of HDL subclasses. <i>Journal of Lipid Research</i> , <b>2010</b> , 51, 1610-7	6.3	21
347	Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. <b>2010</b> , 31, 480-8		96
346	Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. <b>2010</b> , 65, 559-64		46
345	Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?. <b>2010</b> , 8, 345-58		20

344	Lipoproteins and lipoprotein metabolism in periodontal disease. <b>2010</b> , 5, 397-411		29
343	HDL-cholesterol et risque cardiovasculaire : au-delà du LDL ? <b>2010</b> , 4, 379-388		1
342	Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. <b>2010</b> , 50, 1188-201		19
341	High-density lipoprotein and coronary heart disease: current and future therapies. <b>2010</b> , 55, 1283-99		155
340	Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. <i>Clinical Drug Investigation</i> , <b>2010</b> , 30, 51-61	3.2	17
339	HDL cholesterol is a strong determinant of endothelial progenitor cells in hypercholesterolemic subjects. <b>2010</b> , 80, 274-9		28
338	The role of hydrophobic and negatively charged surface patches of lipid-free apolipoprotein A-I in lipid binding and ABCA1-mediated cholesterol efflux. <b>2010</b> , 1801, 64-9		12
337	HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. <i>Atherosclerosis</i> , <b>2010</b> , 208, 3-9	3.1	120
336	[Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?]. <b>2010</b> , 63 Suppl 2, 20-35		18
335	Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. <i>American Journal of Cardiovascular Drugs</i> , <b>2010</b> , 10, 73-84	4	29
334	Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. <b>2011</b> , 27, 814-9		29
333	Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. <b>2011</b> , 27, 1067-78		5
332	HDL: facteur causal de l'athérosclérose ? Arguments physiologiques. <b>2011</b> , 3, 246-253		
331	The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health Outcomes (AIM-HIGH). <b>2011</b> , 161, 471-477.e2		69
330	Low high density lipoprotein cholesterol: prevalence and associated risk-factors in a large French population. <b>2011</b> , 21, 118-27		13
329	Preservation of micronutrients during rapeseed oil refining: a tool to optimize the health value of edible vegetable oils? Rationale and design of the Optim'Oils randomized clinical trial. <b>2011</b> , 32, 233-9		16
328	The role of HDL cholesterol in metabolic syndrome predicting cardiovascular events. The Gubbio population study. <b>2011</b> , 21, 315-22		10
327	[Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study]. <b>2011</b> , 64, 286-94		50



326	Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study. <i>Clinical Drug Investigation</i> , <b>2011</b> , 31, 325-35	3.2	17
325	Prevalence and Characteristics of Lipid Abnormalities in Patients Treated With Statins in Primary and Secondary Prevention in Spain. DYSIS-Spain Study. <b>2011</b> , 64, 286-294		0
324	Down Syndrome and Vascular Disease: DSCR1 and NFAT Signaling. <b>2011</b> ,		
323	. <b>2011</b> ,		1
322	Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL. <b>2011</b> , 199-234		
321	Reducing CVD Risk with Lipid Management This article was first published in British Journal of Cardiac Nursing Vol. 5 No. 9, pp. 410-6. <b>2011</b> , 22, 93-97		
320	Prevalence and associated factors of dyslipidemia in the adult Chinese population. <i>PLoS ONE</i> , <b>2011</b> , 6, e17326	3.7	68
319	Clinical predictors for progression of nonintervened nonculprit coronary lesions despite low-density lipoprotein cholesterol less than 1.8 mmol/l after successful stent implantation. <b>2011</b> , 22, 49-54		4
318	Anacetrapib: a new weapon against dyslipidemia. <b>2011</b> , 6, 227-35		1
317	Structural and biophysical insight into cholesteryl ester-transfer protein. <b>2011</b> , 39, 1000-5		9
316	Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-. <i>Circulation Journal</i> , <b>2011</b> , 75, 1951-9	2.9	29
315	Epidemiology. <b>2011</b> , 113-160		
314	Oxidized low-density lipoprotein is negatively correlated with lecithin-cholesterol acyltransferase activity in type 2 diabetes mellitus. <b>2011</b> , 341, 92-5		17
313	Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. <b>2011</b> , 155, 742-50		39
312	Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers. <b>2011</b> , 33, 754-65		16
311	Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. <b>2011</b> , 365, 2255-67		2046
310	Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. <b>2011</b> , 45, 84-94		27
309	HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. <b>2011</b> , 57, 392-410		341

308	Efficacy of Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High-Risk Patients With or Without Obesity. <b>2011</b> , 1, 1		2
307	Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux. <i>Current Atherosclerosis Reports</i> , <b>2011</b> , 13, 266-76	6	38
306	Imaging apolipoprotein AI in vivo. <b>2011</b> , 24, 916-24		11
305	Chromanol derivatives--a novel class of CETP inhibitors. <b>2011</b> , 21, 488-91		16
304	Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization. <b>2011</b> , 9, 329-40		37
303	The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. <b>2011</b> , 6, 181-208		7
302	Mining the LIPG allelic spectrum reveals the contribution of rare and common regulatory variants to HDL cholesterol. <b>2011</b> , 7, e1002393		28
301	Serum lipid profile of newly diagnosed hypertensive patients in nnewi, South-East Nigeria. <b>2012</b> , 2012, 710486		17
300	Dietary intake of saturated fat by food source and incident cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. <b>2012</b> , 96, 397-404		226
299	High yield expression and purification of recombinant human apolipoprotein A-II in Escherichia coli. <i>Journal of Lipid Research</i> , <b>2012</b> , 53, 1708-15	6.3	12
298	ELISA system for human endothelial lipase. <b>2012</b> , 58, 1656-64		16
297	Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study. <b>2012</b> , 63, 528-34		6
296	The membrane lipid phosphatidylcholine is an unexpected source of triacylglycerol in the liver. <b>2012</b> , 287, 23418-26		47
295	Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort. <i>Journal of Lipid Research</i> , <b>2012</b> , 53, 266-72	6.3	17
294	The Srb1+1050T allele is associated with metabolic syndrome in children but not with cholesteryl ester plasma concentrations of high-density lipoprotein subclasses. <b>2012</b> , 10, 110-6		10
293	Torcetrapib impairs endothelial function in hypertension. <b>2012</b> , 33, 1615-24		61
292	Improving atherosclerosis risk assessment: looking beyond plaque accumulation to imaging of embolization and healing. <b>2012</b> , 7, 29-36		
291	Anti-inflammatory approaches to reduce acute cardiovascular events: not only benefits. <b>2012</b> , 13, 27-36		

290	Should raising high-density lipoprotein cholesterol be a matter of debate?. <b>2012</b> , 13, 254-9		11
289	High-density lipoprotein levels and risk of cardiovascular events: a review. <b>2012</b> , 13, 575-86		17
288	HDL-cholesterol and prediction of coronary heart disease: modified by physical fitness? A 28-year follow-up of apparently healthy men. <i>Atherosclerosis</i> , <b>2012</b> , 220, 250-6	3.1	17
287	[Prevalence of inappropriate LDL cholesterol levels in patients with coronary disease and/or type 2 diabetes]. <b>2012</b> , 212, 475-81		22
286	High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities. <b>2012</b> , 65, 305-308		1
285	Should HDL cholesterol levels be the primary target of cardiovascular disease risk assessment and therapy?. <b>2012</b> , 10, 675-7		
284	Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. <i>Journal of the American Heart Association</i> , <b>2012</b> , 1,	6	93
283	High-density lipoprotein and cardiovascular risk reduction: promises and realities. <b>2012</b> , 65, 305-8		10
282	Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. <b>2012</b> , 163, 515-21, 521.e1-3		45
281	Serum high-density lipoprotein cholesterol levels as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension. <b>2012</b> , 110, 433-9		25
280	Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. <b>2012</b> , 9, 25		65
279	Drugs targeting high-density lipoprotein cholesterol for coronary artery disease management. <b>2012</b> , 28, 667-77		4
278	High hydrostatic pressure extract of garlic increases the HDL cholesterol level via up-regulation of apolipoprotein A-I gene expression in rats fed a high-fat diet. <b>2012</b> , 11, 77		7
277	Paraoxonase 1 (PON1) Activity, Polymorphisms and Coronary Artery Disease. <b>2012</b> ,		
276	Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib. <i>Vascular Health and Risk Management</i> , <b>2012</b> , 8, 483-93	4.4	7
275	Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany. <b>2012</b> , 13, 365-74		7
274	Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors. <b>2012</b> , 22, 3056-62		24
273	Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors. <b>2012</b> , 22, 3671-5		7

272	Low high-density lipoprotein 3 reduces the odds of men surviving to age 85 during 53-year follow-up. <b>2012</b> , 60, 430-6		11
271	Optimal lipid targets for the new era of cardiovascular prevention. <b>2012</b> , 1254, 106-14		2
270	LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. <b>2012</b> , 1254, 18-32		115
269	Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. <i>Current Atherosclerosis Reports</i> , <b>2012</b> , 14, 1-10	6	215
268	Targeting High-Density Lipoprotein and Triglycerides in Statin-Treated Patients with Diabetes. <b>2012</b> , 6, 102-107		1
267	[HDL level or HDL function as the primary target in preventive cardiology]. <b>2012</b> , 37, 51-5		4
266	Hyperlipidemia modifies innate immune responses to lipopolysaccharide via the TLR-NF- $\kappa$ B signaling pathway. <b>2013</b> , 36, 968-76		18
265	High-density lipoproteins: a consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , <b>2013</b> , 7, 484-525	4-9	215
264	Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. <b>2013</b> , 145, 1271-9.e1-3		61
263	Lipid profile in Egyptian patients with coronary artery disease. <b>2013</b> , 65, 79-85		6
262	How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. <b>2013</b> , 166, 8-14		49
261	Modulation of human postprandial lipemia by changing ratios of polyunsaturated to saturated (P/S) fatty acid content of blended dietary fats: a cross-over design with repeated measures. <b>2013</b> , 12, 122		12
260	Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). <b>2013</b> , 112, 1057-62		13
259	Impact of low-density lipoprotein to high-density lipoprotein ratio on aortic arch atherosclerosis in unexplained stroke. <b>2013</b> , 326, 83-8		7
258	Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). <b>2013</b> , 62, 1826-33		65
257	New Treatment Approaches for Dyslipidemia and its Management. <b>2013</b> , 7, 395-400		
256	High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. <b>2013</b> , 34, 3563-71		85
255	Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. <b>2013</b> , 44, 2688-93		23

254	In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. <i>Journal of Lipid Research</i> , <b>2013</b> , 54, 1964-71	6.3	20
253	β-Adrenoceptor activation attenuates atherosclerotic plaque formation in ApoE(-/-) mice through lowering blood lipids and glucose. <b>2013</b> , 34, 1156-63		12
252	Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin. <b>2013</b> , 2013, 612038		13
251	Helical domains that mediate lipid solubilization and ABCA1-specific cholesterol efflux in apolipoproteins C-I and A-II. <i>Journal of Lipid Research</i> , <b>2013</b> , 54, 1939-48	6.3	19
250	Recalculation of 23 mouse HDL QTL datasets improves accuracy and allows for better candidate gene analysis. <i>Journal of Lipid Research</i> , <b>2013</b> , 54, 984-94	6.3	4
249	Designer laying hen diets to improve egg fatty acid profile and maintain sensory quality. <b>2013</b> , 1, 324-35		14
248	Joint effect of high-density lipoprotein cholesterol and low-density lipoprotein cholesterol on the risk of coronary heart disease. <b>2013</b> , 20, 89-97		16
247	High-density lipoprotein cholesterol level is associated with fibrous cap thickness in acute coronary syndrome. <i>Circulation Journal</i> , <b>2013</b> , 77, 2982-9	2.9	20
246	An association study between genetic polymorphisms related to lipoprotein-associated phospholipase A(2) and coronary heart disease. <b>2013</b> , 5, 742-750		19
245	Hypercholesterolemia and in-vivo coronary plaque composition in patients with coronary artery disease: a virtual histology - intravascular ultrasound study. <b>2013</b> , 43, 23-8		3
244	Effects of the <i>Cynanchum wilfordii</i> Ethanol Extract on the Serum Lipid Profile in Hypercholesterolemic Rats. <b>2013</b> , 18, 157-62		22
243	Emergent biomarkers of residual cardiovascular risk in patients with low HDL-c and/or high triglycerides and average LDL-c concentrations: focus on HDL subpopulations, Oxidized LDL, adiponectin, and uric acid. <b>2013</b> , 2013, 387849		7
242	Dietary squalene increases high density lipoprotein-cholesterol and paraoxonase 1 and decreases oxidative stress in mice. <i>PLoS ONE</i> , <b>2014</b> , 9, e104224	3.7	30
241	A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit. <i>PLoS ONE</i> , <b>2014</b> , 9, e111529	3.7	27
240	Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease. <b>2014</b> , 10, 815-23		19
239	Progression from metabolically benign to at-risk obesity in perimenopausal women: a longitudinal analysis of study of women across the nation (SWAN). <b>2014</b> , 99, 2516-25		20
238	How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations. <b>2014</b> , 10, e1003987		15
237	Genomics and Pharmacogenomics of Lipid-Lowering Therapies. <b>2014</b> , 715-746		

236	Evaluation of the effect of andrographolide on atherosclerotic rabbits induced by <i>Porphyromonas gingivalis</i> . <b>2014</b> , 2014, 724718		6
235	Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. <b>2014</b> , 45, 1429-36		48
234	Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. <i>Journal of Lipid Research</i> , <b>2014</b> , 55, 2167-77	6.3	35
233	Beginning to understand high-density lipoproteins. <b>2014</b> , 43, 913-47		70
232	HDL quality and functionality: what can proteins and genes predict?. <b>2014</b> , 12, 521-32		23
231	Anacetrapib: a potential new therapy for dyslipidemia. <b>2014</b> , 22, 253-61		2
230	Low high-density lipoprotein cholesterol is characterized by elevated oxidative stress. <b>2014</b> , 65, 927-31		5
229	HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack. <i>Global Cardiology Science &amp; Practice</i> , <b>2014</b> , 2014, 235-40	0.7	3
228	Cubilin maintains blood levels of HDL and albumin. <b>2014</b> , 25, 1028-36		37
227	Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. <b>2014</b> , 13, 159		116
226	Secular trends in serum lipid levels of a Middle Eastern adult population; 10 years follow up in Tehran lipid and glucose study. <b>2014</b> , 13, 20		24
225	HDL-targeted therapies: progress, failures and future. <b>2014</b> , 13, 445-64		233
224	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. <b>2014</b> , 349, g4379		297
223	The therapeutic role of niacin in dyslipidemia management. <b>2014</b> , 19, 141-58		41
222	Diabetic dyslipidemia. <b>2014</b> , 63, 1469-79		226
221	Linoleic acid suppresses cholesterol efflux and ATP-binding cassette transporters in murine bone marrow-derived macrophages. <b>2014</b> , 49, 415-22		4
220	HDL: to treat or not to treat?. <i>Current Atherosclerosis Reports</i> , <b>2014</b> , 16, 429	6	11
219	Changes of serum parameters of TiO <sub>2</sub> nanoparticle-induced atherosclerosis in mice. <b>2014</b> , 280, 364-71		31

218	Water dispersible plant sterol formulation shows improved effect on lipid profile compared to plant sterol esters. <b>2014</b> , 6, 280-289		16
217	Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. <b>2014</b> , 29, 313-9		11
216	Imaging of native high-density lipoprotein in human coronary plaques by color fluorescent angiography. <i>Circulation Journal</i> , <b>2014</b> , 78, 1667-75	2.9	3
215	High-density lipoprotein cholesterol increases following a short-term yoga-based lifestyle intervention: a non-pharmacological modulation. <b>2014</b> , 69, 543-9		15
214	Neutrophil-lymphocyte ratio is associated with low high-density lipoprotein cholesterol in healthy young men. <b>2014</b> , 2, 2050312114532079		3
213	Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia. <b>2015</b> , 29, 362-70		7
212	Effects of age, sex, and menopausal status on blood cholesterol profile in the Korean population. <b>2015</b> , 45, 141-8		21
211	Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. <i>PLoS ONE</i> , <b>2015</b> , 10, e0118393	3.7	86
210	Prevalence of dyslipidaemia and associated risk factors in a rural population in South-Western Uganda: a community based survey. <i>PLoS ONE</i> , <b>2015</b> , 10, e0126166	3.7	36
209	The High Prevalence of Low HDL-Cholesterol Levels and Dyslipidemia in Rural Populations in Northwestern China. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144104	3.7	23
208	Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics. <b>2015</b> , 296417		19
207	High-density lipoprotein cholesterol: origins and the path ahead. <b>2015</b> , 22, 133-41		11
206	Relation between paradoxical decrease in high-density lipoprotein cholesterol levels after statin therapy and adverse cardiovascular events in patients with acute myocardial infarction. <b>2015</b> , 115, 411-6		9
205	Antisense oligonucleotides, microRNAs, and antibodies. <i>Handbook of Experimental Pharmacology</i> , <b>2015</b> , 224, 649-89	3.2	7
204	Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib. <b>2015</b> , 762, 256-62		7
203	Increased plasma monocyte chemoattractant protein-1 levels in patients with isolated low high-density lipoprotein cholesterol. <b>2015</b> , 75, 327-32		14
202	Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis. <b>2015</b> , 101, 847-53		13
201	High prevalence of cardiovascular disease in South Asians: Central role for brown adipose tissue?. <b>2015</b> , 52, 150-7		11

200	Epidemiology: disease associations and modulators of HDL-related biomarkers. <i>Handbook of Experimental Pharmacology</i> , <b>2015</b> , 224, 259-83	3.2	4
199	Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading. <b>2015</b> , 66, 1470-85		78
198	Identification of the Best Anthropometric Predictors of Serum High- and Low-Density Lipoproteins Using Machine Learning. <b>2015</b> , 19, 1747-56		11
197	Beta2-adrenergic activity modulates vascular tone regulation in lecithin:cholesterol acyltransferase knockout mice. <b>2015</b> , 74, 114-121		14
196	Low concentrations of phospholipids and plasma HDL cholesterol subclasses in asymptomatic subjects with high coronary calcium scores. <i>Atherosclerosis</i> , <b>2015</b> , 238, 250-5	3.1	16
195	Chest Pain. <b>2015</b> , 421-439		
194	Learning from biology: synthetic lipoproteins for drug delivery. <b>2015</b> , 7, 298-314		42
193	HDL and atherosclerosis: Insights from inherited HDL disorders. <b>2015</b> , 1851, 13-8		42
192	11. Cholesterol and fatty acid content and health effects in grass-fed and conventionally raised grain-fed beef. <b>2016</b> , 191-202		
191	Protection from Cardiovascular Disease Due to Increased High-Density Lipoprotein Cholesterol in African Black Populations: Myth or Reality?. <b>2016</b> , 26, 553-560		9
190	Cardiovascular risk prediction: a comparative study of Framingham and quantum neural network based approach. <b>2016</b> , 10, 1259-70		29
189	High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis. <b>2016</b> , 31, 223-9		31
188	Genetics of Dyslipidemia. <b>2016</b> , 106, 434-8		12
187	Effects of improved fat meat products consumption on emergent cardiovascular disease markers of male volunteers at cardiovascular risk. <b>2016</b> , 72, 669-678		4
186	Variations in HDL-carried miR-223 and miR-135a concentrations after consumption of dietary trans fat are associated with changes in blood lipid and inflammatory markers in healthy men - an exploratory study. <b>2016</b> , 11, 438-48		21
185	Cardiovascular Disease Risk Associated With the Long-term Use of Depot Medroxyprogesterone Acetate. <b>2016</b> , 352, 487-492		5
184	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. <b>2016</b> , 39, 329-37		5
183	A study of the prevalence of dyslipidemia among the adult population of Ahvaz, Iran. <b>2016</b> , 10, 190-193		6



182	High intake of regular-fat cheese compared with reduced-fat cheese does not affect LDL cholesterol or risk markers of the metabolic syndrome: a randomized controlled trial. <b>2016</b> , 104, 973-981		34
181	A novel pentacyclic triterpenoid, Ilexgenin A, shows reduction of atherosclerosis in apolipoprotein E deficient mice. <i>International Immunopharmacology</i> , <b>2016</b> , 40, 115-124	5.8	29
180	Functionality of High-Density Lipoprotein as Antiatherosclerotic Therapeutic Target. <b>2016</b> , 36, e87-e94		12
179	Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease. <b>2016</b> , 13, 20		14
178	ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia. <i>Journal of Lipid Research</i> , <b>2016</b> , 57, 1059-73	6.3	12
177	Novel risk factors for acute coronary syndromes and emerging therapies. <b>2016</b> , 220, 815-24		7
176	Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 314-22	4.9	4
175	High apolipoprotein M serum levels correlate with chronic obstructive pulmonary disease. <b>2016</b> , 15, 59		11
174	HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications. <b>2016</b> , 15, 76		8
173	HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients. <b>2016</b> , 27, 595-603		58
172	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. <b>2016</b> , 17, 275-81		8
171	HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target. <i>Current Atherosclerosis Reports</i> , <b>2016</b> , 18, 2	6	43
170	Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 528-537.e3	4.9	10
169	Cholesterol crystal as a new feature of coronary vulnerable plaques: An optical coherence tomography study. <b>2017</b> , 69, 253-259		27
168	Human pericoronary adipose tissue as storage and possible supply site for oxidized low-density lipoprotein and high-density lipoprotein in coronary artery. <b>2017</b> , 69, 236-244		12
167	Intake of up to 3 Eggs per Day Is Associated with Changes in HDL Function and Increased Plasma Antioxidants in Healthy, Young Adults. <b>2017</b> , 147, 323-329		39
166	The risk profile of patients with acute coronary syndrome treated at IKEM between 2006 and 2013. <b>2017</b> , 59, e119-e127		4
165	The HDL cholesterol/apolipoprotein A-I ratio: an indicator of cardiovascular disease. <b>2017</b> , 24, 148-153		18

164	Changes in high-density lipoprotein-carried miRNA contribution to the plasmatic pool after consumption of dietary trans fat in healthy men. <b>2017</b> , 9, 669-688		18
163	Interaction Between the Haptoglobin Genotype and Vitamin E on Cardiovascular Disease in Diabetes. <b>2017</b> , 17, 42		17
162	Low high-density lipoprotein cholesterol and particle concentrations are associated with greater levels of endothelial activation markers in Multi-Ethnic Study of Atherosclerosis participants. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 955-963.e3	4.9	2
161	Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. <b>2017</b> , 376, 1933-1942		406
160	Dyslipidemia management update. <b>2017</b> , 33, 47-55		31
159	Plasma -Fatty Acid Concentrations Continue to Be Associated with Serum Lipid and Lipoprotein Concentrations among US Adults after Reductions in -Fatty Acid Intake. <b>2017</b> , 147, 896-907		21
158	NMR-Based Lipid Profiling of High Density Lipoprotein Particles in Healthy Subjects with Low, Normal, and Elevated HDL-Cholesterol. <b>2017</b> , 16, 1605-1616		15
157	Analysis of Lipoprotein Subfractions in 920 Patients With and Without Type 2 Diabetes. <b>2017</b> , 26, 211-218		6
156	Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 1192-1200.e3	4.9	4
155	Total HDL cholesterol efflux capacity in healthy children - Associations with adiposity and dietary intakes of mother and child. <b>2017</b> , 27, 70-77		6
154	Synthesis of novel Epropanamides to inhibit cholesteryl ester transfer protein (CETP). <b>2017</b> , 28, 260-263		
153	Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes. <b>2017</b> , 32, 549-557		19
152	Cardiovascular disease risk in people with spinal cord injury: is there a possible association between reduced lung function and increased risk of diabetes and hypertension?. <b>2017</b> , 55, 87-93		6
151	Differential expression of osteopontin, and osteoprotegerin mRNA in epicardial adipose tissue between patients with severe coronary artery disease and aortic valvular stenosis: association with HDL subclasses. <b>2017</b> , 16, 156		11
150	Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants. <b>2017</b> , 9,		23
149	Neural Network-Based Coronary Heart Disease Risk Prediction Using Feature Correlation Analysis. <b>2017</b> , 2017, 2780501		41
148	Nonlinear dynamics of early atherosclerotic plaque formation may determine the efficacy of high density lipoproteins (HDL) in plaque regression. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187674	3.7	19
147	Effect of low and high HDL-C levels on the prognosis of lupus nephritis patients: a prospective cohort study. <b>2017</b> , 16, 232		2

146	Prevalence of Conventional Risk Factors and Evaluation of Baseline Indices Among Young and Elderly Patients with Coronary Artery Disease. <b>2017</b> , 11, OC34-OC39		7
145	Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. <i>Journal of Clinical Lipidology</i> , <b>2018</b> , 12, 488-497	4.9	11
144	High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals. <i>Atherosclerosis</i> , <b>2018</b> , 269, 92-99	3.1	8
143	Molecular dynamics simulations of lipid nanodiscs. <b>2018</b> , 1860, 2094-2107		14
142	High-density lipoprotein suppresses tumor necrosis factor alpha production by mycobacteria-infected human macrophages. <i>Scientific Reports</i> , <b>2018</b> , 8, 6736	4.9	12
141	Tertiary structure of apolipoprotein A-I in nascent high-density lipoproteins. <b>2018</b> , 115, 5163-5168		22
140	PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. <b>2018</b> , 20, 270-282		18
139	Dietary supplementation of defatted kenaf ( <i>Hibiscus cannabinus</i> L.) seed meal and its phenolics-saponins rich extract effectively attenuates diet-induced hypercholesterolemia in rats. <b>2018</b> , 9, 925-936		7
138	Cardioprotective Effects of High-Density Lipoprotein Beyond its Anti-Atherogenic Action. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2018</b> , 25, 985-993	4	23
137	Weather Scenario Generation Game. <b>2018</b> ,		
136	Visualization Analysis of Microscopic Surface Topography on Ultra-Precision Optical Components. <b>2018</b> ,		
135	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. <b>2018</b> , 104, 244-256		8
134	Pharmacological Intervention to Modulate HDL: What Do We Target?. <b>2017</b> , 8, 989		25
133	Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention. <b>2018</b> , 17, 21		1
132	Complete and Partial Lecithin:Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis. <i>Circulation</i> , <b>2018</b> , 138, 1000-1007	16.7	35
131	Plasma metabolites reveal distinct profiles associating with different metabolic risk factors in monozygotic twin pairs. <b>2019</b> , 43, 487-502		9
130	The effects of cigarette smoking and smoking cessation on high-density lipoprotein functions: implications for coronary artery disease. <b>2019</b> , 56, 100-111		4
129	Evaluation of Molecularly Imprinted Polymers for Point-of-Care Testing for Cardiovascular Disease. <b>2019</b> , 19,		16

128	Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapy. <b>2019</b> , 15, 65-71		4
127	Trends in Lipids and Lipoproteins Among Adults in Northwestern Xinjiang, China, From 1998 Through 2015. <b>2019</b> , 29, 257-263		9
126	Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients. <b>2019</b> , 70, 98-107		14
125	High-Sensitivity Troponin Assays in Clinical Diagnostics of Acute Coronary Syndrome. <b>2019</b> , 1929, 645-662		2
124	Effectiveness of black tea versus placebo in subjects with hypercholesterolemia: A PRISMA systematic review and meta-analysis. <b>2019</b> , 13, 2250-2258		2
123	Atorvastatin and Fenofibrate Increase the Content of Unsaturated Acyl Chains in HDL and Modify In Vivo Kinetics of HDL-Cholesteryl Esters in New Zealand White Rabbits. <b>2019</b> , 20,		5
122	High-density lipoprotein ameliorates palmitic acid-induced lipotoxicity and oxidative dysfunction in H9c2 cardiomyoblast cells via ROS suppression. <b>2019</b> , 16, 36		57
121	Body mass index and glucocorticoid dose contribute to subclinical atherosclerosis in Korean patients with systemic lupus erythematosus: A prospective 4 year follow-up study. <b>2019</b> , 22, 1410-1418		6
120	Paraoxonase-1 activities in individuals with different HDL circulating levels: Implication in reverse cholesterol transport and early vascular damage. <i>Atherosclerosis</i> , <b>2019</b> , 285, 64-70	3.1	19
119	A Benchmark and Validation of Bifacial PV Irradiance Models. <b>2019</b> ,		5
118	Design and Analysis of Dual Frequency Quarterwave Shorted Microstrip Patch Antenna for Satellite MIMO. <b>2019</b> ,		2
117	Introduction to APDCM 2019. <b>2019</b> ,		
116	Comparison of Brain Networks Based on Predictive Models of Connectivity. <b>2019</b> ,		1
115	. <b>2019</b> ,		
114	Localization Using Saw Rfid Sensor Based on Kalman Algorithm. <b>2019</b> ,		0
113	Optimization of Single-Phase Induction Motor. <b>2019</b> ,		2
112	Distributed Finite-Time Coordination Control system for Economical Operation of Islanded DC Microgrids. <b>2019</b> ,		2
111	A Review on Vision Based Control of Autonomous Vehicles Using Artificial Intelligence Techniques. <b>2019</b> ,		3

110	A Dynamic Rectified Linear Activation Units. <b>2019</b> , 7, 180409-180416	3
109	Learning Data Transformations with Minimal User Effort. <b>2019</b> ,	0
108	EDTM 2019 Copyright Page. <b>2019</b> ,	
107	Faster R-CNN Based Indoor Flame Detection for Firefighting Robot. <b>2019</b> ,	1
106	Solid-State Transformers Technology and Its Applications. <b>2019</b> ,	
105	An Improvement in Performance and Computational Cost of ANN Based Wind Speed Prediction System. <b>2019</b> ,	
104	Edge AI and Blockchain for Privacy-Critical and Data-Sensitive Applications. <b>2019</b> ,	9
103	Dependency and utilization aware Task Allocation for Multi-core Embedded Processors. <b>2019</b> ,	2
102	An Active Vision Based Localization and Mapping Method for MAV Inspection in Visual-degraded Restricted Environment. <b>2019</b> ,	
101	[Copyright notice]. <b>2019</b> ,	
100	The specific of 3D passive radars sensing alive and non-alive objects. <b>2019</b> ,	0
99	Resilience Evaluations of a Wide-area Distributed System with a SDN-FIT system. <b>2019</b> ,	0
98	Individual Similarity Guided Transfer Modeling for EEG-based Emotion Recognition. <b>2019</b> ,	6
97	A Reactive Power Compensation Strategy in Radial Distribution Network with High PV Penetration. <b>2019</b> ,	3
96	. <b>2019</b> ,	
95	. <b>2019</b> ,	16
94	MapReduce-based Dragonfly Algorithm for large-scale Data-Clustering. <b>2019</b> ,	
93	Indicator-based modified genetic approach for power network reconfiguration. <b>2019</b> ,	

92	An FPGA Accelerator for Embedded Microcontrollers Implementing a Ternarized Backpropagation Algorithm. <b>2019</b> ,		1
91	Application of Distributed Machine Learning Model in Fault Diagnosis of Air Preheater. <b>2019</b> ,		1
90	Single Diode Parameter Extraction from In-Field Photovoltaic I-V Curves on a Single Board Computer. <b>2019</b> ,		3
89	Paraoxonase 3: Structure and Its Role in Pathophysiology of Coronary Artery Disease. <i>Biomolecules</i> , <b>2019</b> , 9,	5.9	9
88	Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?. <i>American Journal of Cardiovascular Drugs</i> , <b>2019</b> , 19, 229-235	4	
87	HDL and cardiovascular disease. <i>Pathology</i> , <b>2019</b> , 51, 142-147	1.6	30
86	Subclinical myocardial dysfunction in coronary slow flow phenomenon: Identification by speckle tracking echocardiography. <i>Microcirculation</i> , <b>2019</b> , 26, e12509	2.9	4
85	Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis. <i>Progress in Lipid Research</i> , <b>2019</b> , 73, 65-91	14.3	98
84	Lipoprotein Subfractions in Patients with Acute Coronary Syndromes: Should we Reach Beyond LDL-C?. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 376-378	3.3	2
83	Dietary dilemmas over fats and cardiometabolic risk. <i>Proceedings of the Nutrition Society</i> , <b>2020</b> , 79, 11-21.	2.9	7
82	High-density lipoprotein cholesterol efflux capacity is not associated with atherosclerosis and prevalence of cardiovascular outcome: The CODAM study. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 122-132.	4.9	11
81	Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention. <i>Current Atherosclerosis Reports</i> , <b>2020</b> , 22, 76	6	2
80	MR-LDP: a two-sample Mendelian randomization for GWAS summary statistics accounting for linkage disequilibrium and horizontal pleiotropy. <i>NAR Genomics and Bioinformatics</i> , <b>2020</b> , 2, lqaa028	3.7	10
79	Meta-Analysis of Dyslipidemia Management for the Prevention of Ischemic Stroke Recurrence in China. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 483570	4.1	2
78	Epigallocatechin-3-gallate ameliorates glucolipid metabolism and oxidative stress in type 2 diabetic rats. <i>Diabetes and Vascular Disease Research</i> , <b>2020</b> , 17, 1479164120966998	3.3	8
77	Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies. <i>Scientific Reports</i> , <b>2020</b> , 10, 7715	4.9	14
76	Low Vitamin D Serum Level Is Associated with HDL-C Dyslipidemia and Increased Serum Thrombomodulin Levels of Insulin-Resistant Individuals. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2020</b> , 13, 1599-1607	3.4	5
75	Big-Data-Driven and AI-Based Framework to Enable Personalization in Wireless Networks. <i>IEEE Communications Magazine</i> , <b>2020</b> , 58, 18-24	9.1	11

74	Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5	6
73	Caching and Storage Optimizations for Big Data Streaming Systems. <b>2020</b> ,		0
72	Signal-Transformation-Based Repetitive Control of Spiral Trajectory for Piezoelectric Nanopositioning Stages. <i>IEEE/ASME Transactions on Mechatronics</i> , <b>2020</b> , 25, 1634-1645	5.5	12
71	Experimental Analysis of Interference-Fit Joining of Aluminum Tubes by Electromagnetic Forming. <i>IEEE Transactions on Applied Superconductivity</i> , <b>2020</b> , 30, 1-6	1.8	10
70	. <i>IEEE Transactions on Antennas and Propagation</i> , <b>2020</b> , 68, 4344-4353	4.9	8
69	Transmit Beamforming Based on 4-D Antenna Arrays for Low Probability of Intercept Systems. <i>IEEE Transactions on Antennas and Propagation</i> , <b>2020</b> , 68, 3625-3634	4.9	8
68	Design and analysis of DC voltage synchronisation control for a VSC-MTDC based on virtual synchronous generator. <i>IET Generation, Transmission and Distribution</i> , <b>2020</b> , 14, 449-459	2.5	3
67	Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	15
66	Research on the Application Strategy of Automation Technology in Electronic Information Engineering Design System. <b>2020</b> ,		
65	34.1 A 64B4 Implantable Real-Time Single-Charged-Particle Radiation Detector for Cancer Therapy. <b>2020</b> ,		
64	Equivalent 3-Level PWM: An Improved Technique to Reduce Torque Ripple in DI-WRIM Analyzed as DI-OWIM. <i>IEEE Transactions on Industrial Electronics</i> , <b>2021</b> , 68, 2108-2119	8.9	4
63	Angiopoietin-like 3 inhibition of endothelial lipase is not modulated by angiopoietin-like 8. <i>Journal of Lipid Research</i> , <b>2021</b> , 62, 100112	6.3	3
62	JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases. <i>Circulation Journal</i> , <b>2021</b> , 85, 402-572	5.7	11
61	Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e016947	6	10
60	Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>2021</b> , 168, 102282	2.8	
59	Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis. <i>International Immunopharmacology</i> , <b>2021</b> , 94, 107466	5.8	4
58	Changes in lipid profile and some biochemical parameters in postmenopausal women treated with honey. <i>Journal of Preventive Medicine and Holistic Health</i> , <b>2021</b> , 7, 31-36		
57	The Role of Paraoxonase in Lipid Metabolism. <b>2002</b> , 79-92		5

56	Cellular cholesterol efflux is modulated by phospholipid-derived signaling molecules in familial HDL deficiency/Tangier disease fibroblasts. <i>Journal of Lipid Research</i> , <b>2001</b> , 42, 249-257	6.3	26
55	In vitro factors affecting the concentration of gamma-LpE (β <sub>2</sub> -LpE) in human plasma. <i>Journal of Lipid Research</i> , <b>1998</b> , 39, 861-872	6.3	22
54	Differential response to low-fat diet between low and normal HDL-cholesterol subjects. <i>Journal of Lipid Research</i> , <b>2000</b> , 41, 321-328	6.3	40
53	Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL. <i>Clinical Science</i> , <b>2019</b> , 133, 2221-2235	6.5	12
52	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. <i>European Heart Journal Supplements</i> , <b>2017</b> , 19, D3-D54	1.5	11
51	A Novel Cell-Free Fluorescent Assay for HDL Function: Low Apolipoprotein A1 Exchange Rate Associated with Increased Incident Cardiovascular Events. <i>Journal of Applied Laboratory Medicine</i> , <b>2020</b> , 5, 544-557	2	5
50	A Photo-Activatable Peptide Mimicking Functions of Apolipoprotein A-I. <i>Biological and Pharmaceutical Bulletin</i> , <b>2019</b> , 42, 1019-1024	2.3	4
49	High density lipoprotein stimulated migration of macrophages depends on the scavenger receptor class B, type I, PDZK1 and Akt1 and is blocked by sphingosine 1 phosphate receptor antagonists. <i>PLoS ONE</i> , <b>2014</b> , 9, e106487	3.7	32
48	Effect of black tea consumption on blood cholesterol: a meta-analysis of 15 randomized controlled trials. <i>PLoS ONE</i> , <b>2014</b> , 9, e107711	3.7	20
47	Structural and Functional Analysis of the ApolipoproteinA-I A164S Variant. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143915	3.7	12
46	Localization of native high-density lipoprotein and its relation to plaque morphology in human coronary artery. <i>International Heart Journal</i> , <b>2013</b> , 54, 348-54	1.8	2
45	Simultaneous transfer of cholesterol, triglycerides, and phospholipids to high-density lipoprotein in aging subjects with or without coronary artery disease. <i>Clinics</i> , <b>2011</b> , 66, 1543-8	2.3	8
44	Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). <i>Profilakticheskaya Meditsina</i> , <b>2016</b> , 19, 15	0.5	19
43	Comparison of Two Types of Diets on Losing Weight and Lipid Profile of Overweight/Obese Middle-Aged Women Under Exercise Condition. <i>Health Scope</i> , <b>2014</b> , 3,	1.1	3
42	Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. <i>Vascular Health and Risk Management</i> , <b>2005</b> , 1, 119-29	4.4	49
41	CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?. <i>Global Cardiology Science &amp; Practice</i> , <b>2016</b> , 2016, e201634	0.7	3
40	Effects of Saengshik Supplementation on Health Improvement in Diet-Induced Hypercholesterolemic Rats. <i>Journal of the Korean Society of Food Science and Nutrition</i> , <b>2003</b> , 32, 906-912	1.5	28
39	A new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 5946-52	5.6	18



38	To Investigate the Relation of Hypertension and Anthropometric Measurement among Elderly in Malaysia. <i>Journal of Applied Sciences</i> , <b>2008</b> , 8, 3963-3968	0.3	11
37	Changes in Lipid Profiles in Two Groups of HIV-1 Infected Patients in Cameroon on Two Treatment Regimens with Either Efavirenz or Nevirapine, in Association with Reverse Transcriptase Inhibitors. <i>Journal of Medical Sciences (Faisalabad, Pakistan)</i> , <b>2010</b> , 10, 25-33	0.5	2
36	Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population. <i>Indian Journal of Endocrinology and Metabolism</i> , <b>2016</b> , 20, 67-71	1.7	4
35	High density lipoprotein and cardiovascular diseases. <i>World Journal of Cardiology</i> , <b>2013</b> , 5, 210-4	2.1	15
34	Life style and cardiovascular risk factors in the Japanese population--from an epidemiological survey on serum lipid levels in Japan 1990 part 1: influence of life style and excess body weight on HDL-cholesterol and other lipid parameters in men. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2003</b> , 10, 165-75	4	22
33	Associations of Serum Lipid Profiles with Incidence of Ischemic Heart Diseases in Korean Adults: Retrospective Cohort Study. <i>Journal of the Korea Academia-Industrial Cooperation Society</i> , <b>2012</b> , 13, 2219-2231 <sup>3</sup>		
32	Sekundäre Fettstoffwechselstörungen: Welche Bedeutung? Welche Therapie?. <b>2000</b> , 333-337		
31	References. <i>Circulation</i> , <b>2002</b> , 106, 3373-3421	16.7	1
30	Utilization of Lipoprotein Subfractions. <b>2007</b> , 321-347		
29	HDL particle as a risk factor for cardiovascular diseases in healthy people. <i>Annales Universitatis Mariae Curie-Sklodowska Sectio DDD Pharmacia</i> , <b>2008</b> , 21, 349-353		
28	Endocannabinoid Receptor Blockers. <b>2009</b> , 339-351		
27	The Effect of Pine (pinus densiflora) Needle Extracts on Blood Flow and Serum Lipid Improvement. <i>Journal of Life Science</i> , <b>2009</b> , 19, 508-513		7
26	Atherosclerosis. <b>2010</b> , 53-67		
25	The Effect of Ecklonia stolonifera Extracts on Blood Flow and Serum Lipid Level in Ovariectomized Rats. <i>Journal of Life Science</i> , <b>2010</b> , 20, 1851-1858		4
24	Isolated Low HDL. <b>2011</b> , 159-171		
23	Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects. <i>Clinical Drug Investigation</i> , <b>2011</b> , 1	3.2	
22	Vitamin D Status, C-Reactive Protein and Risk of Coronary Artery Disease—A Hospital-Based Study. <i>Pharmacology &amp; Pharmacy</i> , <b>2014</b> , 05, 1148-1156	0.3	
21	Obesity and Type 2 Diabetes. <b>2014</b> , 561-570		

20	MR-LDP: a two-sample Mendelian randomization for GWAS summary statistics accounting for linkage disequilibrium and horizontal pleiotropy.		0
19	High-Density Lipoproteins. <i>Contemporary Cardiology</i> , <b>2021</b> , 341-361	0.1	1
18	Clusterin, paraoxonase 1, and myeloperoxidase alterations induce high-density lipoproteins dysfunction and contribute to peripheral artery disease; aggravation by type 2 diabetes mellitus. <i>BioFactors</i> , <b>2021</b> ,	6.1	1
17	Advances in diabetes for the millennium: diabetes and cholesterol. <i>MedGenMed: Medscape General Medicine</i> , <b>2004</b> , 6, 5		
16	Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians. <i>Indian Journal of Medical Research</i> , <b>2013</b> , 138, 873-81	2.9	1
15	The association between the rs10248618 SNP and serum lipid traits, the risk of coronary artery disease, and ischemic stroke. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2018</b> , 11, 4585-4594	1.4	0
14	Fibronectin-containing High-Density Lipoprotein is Associated with Cancer Cell Adhesion and Proliferation. <i>Kobe Journal of Medical Sciences</i> , <b>2020</b> , 66, E40-E48	0.6	1
13	High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?. <i>Handbook of Experimental Pharmacology</i> , <b>2021</b> ,	3.2	0
12	Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.. <i>Pharmaceuticals</i> , <b>2022</b> , 15,	5.2	0
11	High Density Lipoprotein Reduces Blood Pressure and Protects Spontaneously Hypertensive Rats Against Myocardial Ischemia-Reperfusion Injury in an SR-BI Dependent Manner.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9, 825310	5.4	
10	Relationship between Health-Related Physical Fitness Parameters and Functional Movement Screening Scores Acquired from a Three-Dimensional Markerless Motion Capture System.. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19,	4.6	1
9	Table_1.DOCX. <b>2020</b> ,		
8	ABCA1, ABCG1, and Cholesterol Homeostasis.. <i>Advances in Experimental Medicine and Biology</i> , <b>2022</b> , 1377, 95-107	3.6	0
7	Alteration in serum oxidative stress balance in patients with different circulating high-density lipoprotein cholesterol levels. <i>Revista Portuguesa De Cardiologia</i> , <b>2022</b> ,	1	0
6	Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. <b>2022</b> , 23, 9417		0
5	Paradoxical Long-Term Impact Between Serum Apolipoprotein E and High-Density Lipoprotein Cholesterol in Patients Undergoing Percutaneous Coronary Intervention. <b>2022</b> ,		0
4	Efficacy and safety of Pueraria lobata radix and Pueraria thomsonii radix for patients with mild dyslipidemia: A randomized, double-blind, placebo-controlled trial. <b>2022</b> , 98, 105284		0
3	A Clinical Trial of the Effects of a Dietary Pattern on Health Metrics and Fecal Metabolites in Volunteers With Risk of Cardiovascular Disease. 9,		0

- 2 Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease. **2022**, 80, 2104-2115 1
- 1 HDL-Associated Proteins in Subjects with Polycystic Ovary Syndrome: A Proteomic Study. **2023**, 12, 855 0